Hook & Thesis
ResMed (RMD) is getting penalized in some quarters for the narrative that GLP-1 weight-loss drugs will meaningfully shrink the market for sleep apnea devices. That story is easy to repeat but hard to square with the facts: ResMed reported 11% year-over-year revenue growth in the most recent quarter and continues to convert strong earnings into free cash flow of roughly $1.75 billion. The market has bought into a worst-case scenario; my view is that the threat is real but modest and already priced into the stock.
My trade idea is a mid-term long: buy RMD on a measured pullback, target upside driven by product rollouts, recent tuck-in acquisitions, and a gradual multiple recovery as execution meets or beats expectations. Entry at $195.07, stop at $180.00, target at $230.00. This is a trade designed to capture a re-rating and near-term fundamental beats over the next 45 trading days, with a watchful eye toward execution and reimbursement headlines.
What ResMed does and why it matters
ResMed is a health-technology company focused on sleep-disordered breathing and respiratory care. The firm sells CPAP and other therapy devices through the Sleep and Respiratory Care segment, while a Software as a Service segment provides practice and care-management tools to out-of-hospital providers. The mix matters: devices drive recurring consumable sales and recurring patient relationships, while SaaS adds high-margin, sticky revenue that helps smooth device cyclicality.
Why investors should care - three quick points:
- Large and growing market: sleep apnea and related respiratory disorders affect a huge population. Market reports project sleep apnea device market CAGRs in the 7% range, and broader respiratory-care forecasts show similar 7-8% expansion through 2034.
- Strong cash generation and conservative balance sheet: free cash flow is about $1.75 billion and debt-to-equity is low at about 0.10, giving ResMed financial flexibility to invest in adjacent therapies and tuck-in acquisitions.
- Recurring revenue and product innovation: FDA clears AI-enabled devices and the company recently acquired Noctrix Health for $340 million to add neuromodulation and wearable therapies to its portfolio - a diversification away from sole dependence on CPAP.
Numbers that support the bullish view
ResMed's most recent reported quarter (Q2 FY2026) delivered adjusted EPS of $2.81 versus consensus $2.72, and revenue of $1.42 billion, up 11% year-over-year. On a per-share basis, the company posts earnings per share of about $10.48 and trades at a P/E in the high teens - roughly 18.5x based on recent prices. Market capitalization sits near $28.08 billion and enterprise value near $27.08 billion. The company yields roughly 1.2% in cash dividends and maintains a strong return profile - ROE around 23.4% and ROA near 17.3%.
Operationally, ResMed has real levers to offset any partial demand erosion from weight-loss therapies:
- Adjacencies: The Noctrix Health acquisition (announced 06/03/2026) buys an FDA-authorized neuromodulation therapy for restless legs syndrome and will expand ResMed's non-CPAP therapeutic footprint.
- Software and services: SaaS revenue smooths device demand and enhances lifetime value of patients through remote monitoring and care management.
- Global growth: ResMed operates in 140+ countries and benefits from rising homecare adoption globally - the respiratory care market is forecast to expand strongly, with North America leading but substantial upside in Asia and Europe.
Valuation framing
At roughly $28.08 billion market cap and a P/E around 18-19x, ResMed trades meaningfully below its recent five-year average multiples. Analysts have pointed out that the forward P/E sits near 22 - below the five-year average of roughly 29 - which suggests the market is already assuming slower growth or margin pressure. Given the company’s $1.75 billion in free cash flow, low leverage (debt-to-equity ~0.10), and ROE north of 23%, the current valuation looks conservative unless GLP-1s drive a structural and sustained decline in device utilization.
Compare valuation logic qualitatively rather than rely on thin peer comps: ResMed combines durable hardware consumables, high-margin SaaS, recurring revenue, and a solid balance sheet. That mix typically justifies a premium relative to single-product device vendors. At current prices the stock is priced for modest execution risks, not for an existential market collapse.
Technical and market context
Technicals show RMD trading around $195 with a 10-day simple moving average near $192 and a 50-day SMA around $211 - the stock has pulled back from 52-week highs around $293 and tested nearer-term lows of $180 in early June. Short interest has trended elevated with roughly 11.9 million shares short as of late May and days-to-cover in the high single digits; recent short-volume data show persistent bearish trading activity, which can amplify moves but also create squeeze dynamics if fundamentals re-accelerate.
Catalysts to drive the trade
- Near-term earnings beats - management guided to high single-digit revenue growth and double-digit EPS growth; another quarter of upside would force a multiple re-rating.
- Successful integration and commercialization of Noctrix therapies - tangible revenue contribution or clinical wins would broaden the narrative beyond CPAP.
- Positive reimbursement clarity - any confirmation or improvement in Medicare/insurer coverage for diagnostics and durable equipment reduces tail risk.
- Product momentum - adoption of AI-enabled features and the newly cleared Smart Comfort device driving share gains vs incumbents.
Trade plan
Actionable entry / stop / target:
- Entry price: $195.07
- Stop loss: $180.00
- Target price: $230.00
Horizon: This is a mid-term trade - aim for a holding period of 45 trading days (mid term - 45 trading days). That window gives time for quarterly results, early integration updates on Noctrix, and potential favorable headlines on reimbursement or product adoption to materialize. If the stock reaches the target before 45 trading days due to a catalyst-driven re-rating, consider trimming positions into strength. Conversely, if the stock is under pressure but remains above the stop, reevaluate after upcoming quarterly updates.
Risk management and position sizing
Given RMD’s volatility and elevated short interest, position size should reflect a defined capital-at-risk consistent with the stop at $180. Use the stop-loss level tightly; if the market breaks below $180 on heavy volume, the case for a broader structural problem - possibly early signs of accelerating decline in utilization - becomes more likely.
Risks and counterarguments
- GLP-1 adoption reducing severe OSA incidence - The straightforward counterargument is that durable weight loss across a large ensemble of patients could reduce the pool needing CPAP or other devices, especially among mild-to-moderate OSA cases. If prescription rates for GLP-1s accelerate and lead to widespread, sustained weight loss, device demand could decline materially.
- Reimbursement pressure - Medicare or large insurers could reduce coverage or tighten criteria for CPAP and related diagnostics. Given the importance of insured reimbursement for durable devices, adverse policy moves would compress revenue quickly.
- Competitive intensity and pricing pressure - Philips and other competitors could respond with lower-priced therapies or aggressive bundling, pressuring ASPs and consumable attach rates.
- Execution risk on new therapies - The return on the Noctrix purchase depends on smooth integration and commercialization. If the product fails to scale or regulatory scrutiny increases, the diversification thesis weakens.
- Macro or cyclical shocks - A broader risk-off event can compress medtech multiples and impair near-term upside regardless of company fundamentals.
Counterargument to my thesis
Admittedly, the downside scenario is non-trivial: a rapid, broad-based decline in OSA prevalence driven by GLP-1s could lower long-term device demand and structural attach rates for consumables. If that scenario plays out quicker than anticipated, the appropriate multiple could permanently decline, making even current valuation levels look optimistic. I acknowledge this path and price it into a tighter stop and modest position size rather than a full conviction buy.
Conclusion - What would change my mind
My primary stance: GLP-1 threats are overstated relative to the current market price. ResMed’s diversified revenue model, strong cash flow, low leverage, and active product pipeline create an asymmetric risk-reward in the mid-term. Buy at $195.07 with a stop at $180 and a target of $230 over roughly 45 trading days.
I would change my view if one or more of the following occurred: (1) materially weaker consumable attach rates reported for two consecutive quarters; (2) definitive payer policy shifts materially restricting access to CPAP and diagnostics; (3) clinical data showing that GLP-1s eliminate the need for therapy at scale across moderate-to-severe OSA cohorts. Any of these would force a reevaluation of the structural market thesis and warrant a more cautious stance.
Bottom line - This is a measured, data-driven long: buy RMD on a controlled entry, size the position to the stop, and let catalysts - quarterly execution, product rollouts, and integration wins - do the rest.